entertainment -WSS

entertainment

author：hotspot 2025-09-04 05:36:40 - browse：2

Hospital power in DC — Mike Reddy for STAT

WASHINGTON — Democrats unilaterally drove major reforms to the health insurance and the pharmaceutical industries without a single Republican vote in recent years. But hospitals may be a health care giant they’re unable to confront alone.

Unlike Republicans, Democrats have seized on lowering health care costs as a politically winning issue in one election cycle after another. They have campaigned on passing health insurance reform, and then protecting it. And after 20 years, they finally delivered on a promise to empower the federal government to lower drug prices in 2022.

But the remaining elephant in the room is hospital costs, which make up the biggest share of U.S. health care spending. And Democratic leaders in Congress have shown this year that they are unable to agree on even the most incremental steps toward addressing the cost of hospital care.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： NFL doctors' conflicts of interest could endanger players, report says

focus

WSS

Biden administration opens offers in Medicare drug price negotiations

Some dementia cases could be undiagnosed liver disease

The real point of Kenneth Smith’s execution by nitrogen gas

Medicare drug price negotiation’s day in court

Even great ERs can’t make up for American health disparities

Vertex non

hotspot

entertainment

focus

In age of alternative facts, a scholarly course on calling out crap

Slovenia has suffered its worst

In age of alternative facts, a scholarly course on calling out crap

Quicker fix for pulse oximeters urged during FDA public meeting

New air purifier tech could be key to improving indoor air quality

St. Louis police protesters begin picking up checks in $4.9 million settlement

Peter Hotez and the public health issue of online harassment

'Brian's Song' at 50 still offers lessons about cancer for today

Novavax promises a turnaround & Lilly roils the obesity market

A $475,000 price tag for a new cancer drug: crazy or meh?

focus

Paxlovid rebound happens. Why and to whom are still a mystery

Doctors are clamoring for more clarity on Paxlovid prescribing

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Sage considers ways to reduce costs following FDA rejection

Quicker fix for pulse oximeters urged during FDA public meeting

Sage considers ways to reduce costs following FDA rejection

explore

focus

leisure time

Wikipedia